Ellie Leick | Authors

Articles

Osimertinib Established as Preferred EGFR TKI Treatment in EGFR-Mutated NSCLC

November 12, 2019

In an interview with Targeted Oncology during the 14th Annual New York Lung Cancers Symposium, Zofia Piotrowska, MD, MHS, discussed the role of osimertinib in treating patients with EGFR-mutant NSCLC and how it compares with other therapeutic options in that space.

More Research and Development on JAK Inhibition May Improve Myelofibrosis Management

September 15, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Laura C. Michaelis, MD, discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Expert Says Immunotherapy in AML Expanded to New Approaches, Despite Challenges

September 14, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, John F. DiPersio, MD, PhD, discussed the challenges in research surrounding immunotherapies for AML, including DARTs, BiTEs, ADCs, and CARs.